meglumine has been researched along with Alloxan Diabetes in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (45.45) | 29.6817 |
| 2010's | 5 (45.45) | 24.3611 |
| 2020's | 1 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Bazeed, AY; El Maghraby, GM; Essa, EA; Nouh, A | 1 |
| Fan, DX; Hua, ZX; Ren, K; Wang, ST; Zhang, X | 1 |
| Miroshnichenko, IY; Rassokhina, LM; Volchegorskii, IA | 1 |
| Faizullin, RM; Kalugina, AV; Miroshnichenko, IY; Pryakhina, KE; Rassokhina, LM; Volchegorskii, LA | 1 |
| Miroshnichenko, IIu; Rassokhina, LM; Volchegorskiĭ, IA | 2 |
| Ardid, D; Boucher, M; Coudoré-Civiale, MA; Courteix, C; Eschalier, A; Fialip, J; Méen, M | 1 |
| Boucher, M; Coudoré-Civiale, MA; Courteix, C; Eschalier, A; Fialip, J | 1 |
| Kamei, J; Zushida, K | 1 |
| Kamei, J; Nagase, H; Zushida, K | 1 |
| Boucher, M; Coudoré-Civiale, MA; Eschalier, A; Fournié-Zaluski, MC; Méen, M; Roques, BP | 1 |
11 other study(ies) available for meglumine and Alloxan Diabetes
| Article | Year |
|---|---|
Co-processing of nateglinide with meglumine for enhanced dissolution rate:
Topics: Animals; Diabetes Mellitus, Experimental; Meglumine; Nateglinide; Rats; Solubility; Spectroscopy, Fourier Transform Infrared; X-Ray Diffraction | 2020 |
Gadolinium Retention and Clearance in the Diabetic Brain after Administrations of Gadodiamide, Gadopentetate Dimeglumine, and Gadoterate Meglumine in a Rat Model.
Topics: Animals; Brain; Diabetes Mellitus, Experimental; Gadolinium; Gadolinium DTPA; Magnetic Resonance Imaging; Male; Meglumine; Organometallic Compounds; Rats; Rats, Wistar; Time Factors | 2019 |
Cerebroprotective effects of emoxipin, reamberin, and mexidol in alloxan diabetes.
Topics: Alloxan; Animals; Astrocytes; Cerebral Cortex; Diabetes Mellitus, Experimental; Diencephalon; Female; Hippocampus; Hyperglycemia; Male; Meglumine; Neurons; Neuroprotective Agents; Oligodendroglia; Paraventricular Hypothalamic Nucleus; Picolines; Rats; Succinates; Thioctic Acid | 2013 |
[Anxiolytic and antidepressant effects of 3-oxypiridine and succinic acid derivatives in alloxan diabetes].
Topics: Animals; Anti-Anxiety Agents; Anxiety; Depression; Diabetes Mellitus, Experimental; Humans; Hyperglycemia; Meglumine; Picolines; Pyridines; Rats; Succinates; Succinic Acid; Thioctic Acid | 2015 |
[Cerebroprotective effect of 3-oxypyridine and succinic acid derivatives in acute phase of alloxan-induced diabetes mellitus in rats].
Topics: Alloxan; Animals; Antioxidants; Blood Glucose; Diabetes Mellitus, Experimental; Disease Models, Animal; Female; Hippocampus; Learning; Lipid Metabolism; Lipid Peroxidation; Male; Meglumine; Motor Activity; Neurons; Neuroprotective Agents; Nootropic Agents; Picolines; Pyridines; Rats; Succinates; Succinic Acid; Thioctic Acid | 2011 |
[Antihypoxic effect of 3-hydroxypyridine and succinic acid derivatives and their nootropic action in alloxan diabetes].
Topics: Alloxan; Animals; Conditioning, Classical; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Dose-Response Relationship, Drug; Female; Hyperglycemia; Hyperlipidemias; Hypoxia; Male; Meglumine; Mice; Nootropic Agents; Picolines; Pyridines; Rats; Succinates; Thioctic Acid | 2011 |
Potentiation of morphine and clomipramine analgesia by cholecystokinin -B antagonist CI-988 in diabetic rats.
Topics: Analgesia; Analgesics, Opioid; Animals; Anti-Anxiety Agents; Antidepressive Agents, Tricyclic; Clomipramine; Diabetes Mellitus, Experimental; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Indoles; Male; Meglumine; Morphine; Nociceptors; Pain; Pain Threshold; Peripheral Nervous System Diseases; Rats; Rats, Sprague-Dawley; Receptor, Cholecystokinin B; Receptors, Cholecystokinin; Time Factors | 2000 |
Spinal effect of the cholecystokinin-B receptor antagonist CI-988 on hyperalgesia, allodynia and morphine-induced analgesia in diabetic and mononeuropathic rats.
Topics: Analgesia; Analgesics, Opioid; Animals; Diabetes Mellitus, Experimental; Drug Synergism; Hormone Antagonists; Hyperalgesia; Indoles; Injections, Intravenous; Injections, Spinal; Male; Meglumine; Morphine; Nervous System Diseases; Pain Threshold; Rats; Rats, Sprague-Dawley; Receptor, Cholecystokinin B; Receptors, Cholecystokinin; Touch | 2000 |
The role of spinal cholecystokinin B receptors in thermal allodynia and hyperalgesia in diabetic mice.
Topics: Animals; Capsaicin; Cholecystokinin; Diabetes Mellitus, Experimental; Enzyme Activators; Hot Temperature; Hyperalgesia; Indoles; Injections, Spinal; Male; Meglumine; Mice; Mice, Inbred ICR; Nerve Fibers; Nociceptors; Pain; Protein Kinase C; Reaction Time; Receptor, Cholecystokinin B; Receptors, Cholecystokinin; Spinal Cord | 2001 |
Role of cholecystokinin in the reduction of endomorphin-2-induced antinociception in diabetic mice.
Topics: Analgesics; Animals; Behavior, Animal; Cholecystokinin; Diabetes Mellitus, Experimental; Dose-Response Relationship, Drug; Indoles; Injections, Intraventricular; Meglumine; Mice; Mice, Inbred ICR; Nociceptors; Oligopeptides; Pain; Pain Measurement; Sincalide | 2001 |
Enhancement of the effects of a complete inhibitor of enkephalin-catabolizing enzymes, RB 101, by a cholecystokinin-B receptor antagonist in diabetic rats.
Topics: Aminopeptidases; Animals; Diabetes Mellitus, Experimental; Disulfides; Drug Synergism; Indoles; Male; Meglumine; Naloxone; Naltrexone; Neprilysin; Pain; Pain Measurement; Phenylalanine; Pressure; Rats; Rats, Sprague-Dawley; Receptor, Cholecystokinin B; Receptors, Cholecystokinin; Time Factors; Vocalization, Animal; Weight Loss | 2001 |